Status:
UNKNOWN
Yuflyma® (Adalimumab), Patient Experience After Switching
Lead Sponsor:
Celltrion HealthCare France
Conditions:
Rheumatoid Arthritis
Ankylosing Spondylarthritis
Eligibility:
All Genders
18+ years
Brief Summary
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching. A number of factors contribute to this, including their beliefs, fear...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult (aged 18 or older at the time of inclusion) rheumatology or gastroenterology patients presenting a diagnosis for any of the following pathologies : Rheumatoid Arthritis (RA) Ankylosing Spondylarthritis (AS) Axial Spondyloarthritis with no signs of AS (AxSpa) Psoriatic Arthritis (PsA) Crohn's Disease (CD) Ulcerative Colitis (UC)
- Stable and treated for at least 3 months prior to inclusion either with an adalimumab (ADA) biosimilar or originator adalimumab (40 mg dose injections only)
- For whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
- Able to initiate treatment within 4 weeks of inclusion
- Have an email account
- Have a mobile phone number
- Able to understand and complete French-language questionnaires
- Are not opposed to participating in the study.
- Are covered by French National Health Insurance.
- Non inclusion Criteria:
- Patients meeting any of the following exclusion criteria will not be included in the study:
- Patients younger than 18 years old at the date of inclusion
- Patients treated with adalimumab for any other pathology than those specified in the inclusion criteria.
- Patients treated with adalimumab originator 80 mg.
- Patients under curatorship or guardianship or otherwise deprived of liberty
- Patients unable to understand and complete French-language questionnaires
- Pregnant women or women of childbearing potential with a desire of becoming pregnant concomitant to treatment with Yuflyma®.
Exclusion
Key Trial Info
Start Date :
June 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05427942
Start Date
June 3 2022
End Date
March 1 2023
Last Update
June 22 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Private Practice - ES
Marseille, France
2
Private practice GB
Toulouse, France